摘要
目的探讨孟鲁司特钠联合盐酸氮卓斯汀在过敏性鼻炎（AR）患者中的应用效果。方法选取95例AR患者，按照随机数字表法分组，对照组47例给予盐酸氮卓斯汀治疗，观察组48例给予盐酸氯卓斯汀＋孟鲁司特钠治疗，比较两组治疗效果及用药前后血清嗜酸性粒细胞阳离子蛋白（ECP）、炎症因子各指标[肿瘤坏死因子-α（TNF-α）、γ-干扰素（INF-γ）、白细胞介素-6（IL-6）]水平变化情况，并统计两组不良反应发生情况。结果观察组治疗总有效率[91．67％（44／48）]高于对照组[70．21％（33／47）]，差异有统计学意义（P〈0．05）；观察组用药4周后血清ECP水平较对照组低，差异有统计学意义（P〈0．05）；观察组用药4周后血清INF-γ、IL-6及TNF—α水平低于对照组，差异有统计学意义（P〈0．05）；观察组不良反应发生率[10．42％（5／48）]与对照组[4．26％（2／47）]比较，差异未见统计学意义（P〉0．05）。结论孟鲁司特钠联合盐酸氮卓斯汀可减轻AR患者炎症反应，改善血清ECP水平，疗效确切，且安全性高。
Objective To investigate the application effect ofmontelukast sodium combined with azolazine hydrochloride in patients with allergic rhinitis （AR）. Methods A total of 95 cases of AR patients were divided into groups according to the random number table method. Forty-seven cases in the control group were treated with azolazine hydrochloride, and 48 cases in the observation group were treated with azolazine hydroehloride ＋ montelukast sodium. The therapeutic effect and the changes of serum level of eosinophil cationic protein （ECP） and inflammatory factors [ tumor necrosis factor-α （TNF-α）, interferon-γ （INF-γ） and interleukin-6 （IL-6） ] before and after treatment of two groups were observed and compared. And the adverse reactions of two groups were statistically recorded. Results The total effective rate of treatment in the observation group [91.67% （44/48） ] was higher than that of the control group [70. 21% （33/47） ], and the difference was statistically significant（P 〈0. 05）. After 4 weeks of drug use, the level of serum ECP in the observation group was lower than the control group, and the difference was statistically significant（ P 〈 0. 05 ）. The level of serum INF-7, IL-6 and TNF-α in the observation group was lower than that of the control group after 4 weeks of drug use, and the difference was statistically significant （P 〈 0. 05 ）. The incidence of adverse reactions in the observation group was 10. 42% （5/48）, and the control group was 4.26% （2/47）, and The difference was not statistically significant（P 〉 0.05 ）. Conclusions Montelukast sodium combined with azolazine hydrochloride can reduce the inflammatory response in AR patients and improve the level of serum ECP. It is effective and safe.
作者
李剑峰
Li Jianfeng(Department of Otolaryngology, the People＇s Hospital of Shanxi, Taiyuan 030012, China)
出处
《中国实用医刊》
2018年第12期106-109,共4页
Chinese Journal of Practical Medicine
